%0 Journal Article %A KAZUTOSHI OKABE %A TORU BEPPU %A KATSUKI HARAOKA %A YOSHIHIRO OH-UCHIDA %A SADAHIRO YAMAMURA %A SHINJIRO TOMIYASU %A TSUYOSHI YAMANAKA %A OSAMU SANO %A TOSHIRO MASUDA %A AKIRA CHIKAMOTO %A SHIGETOSHI FUJIYAMA %A HIDEO BABA %T Safety and Short-term Therapeutic Effects of Miriplatin–Lipiodol Suspension in Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma %D 2011 %J Anticancer Research %P 2983-2988 %V 31 %N 9 %X Aim: To determine the safety and usefulness of a novel anticancer drug, miriplatin, in transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. Patients and Methods: Patients (n=115) who underwent TACE with miriplatin–lipiodol suspension (miriplatin group), and control patients (n=131) who underwent TACE with cisplatin–lipiodol suspension (CDDP group) took part in this study. Results: The overall incidence of adverse events was significantly lower in the miriplatin group. The percentage of patients attaining treatment effect 4 in both groups was not significantly different. The proportion exhibiting a >50% decrease in positive tumor markers following TACE was significantly greater in the CDDP group for alpha-fetoprotein, but not significantly different for des-gammma-carboxy prothrombin. Conclusion: Miriplatin–lipiodol suspension was associated with reduced intensity of adverse events and had comparable short-term therapeutic effects to cisplatin–lipiodol suspension, thereby indicating its usefulness in TACE. %U https://ar.iiarjournals.org/content/anticanres/31/9/2983.full.pdf